Ticker Details
VistaGen Therapeutics, Inc. VistaGen Therapeutics Inc is a clinical-stage biopharmaceutical company that develops and commercializes product candidates for patients with central nervous system diseases. Its product AV-101 is currently being evaluated in a Phase 2 monotherapy study.
IPO Date:	July 1, 2011
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$22.02M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.08 | 4.04%
Avg Daily Range (30 D):	$0.02 | 3.29%
Avg Daily Range (90 D):	$0.06 | 4.19%

Institutional Daily Volume
Avg Daily Volume:	1.37M
Avg Daily Volume (30 D):	.4M
Avg Daily Volume (90 D):	1.71M

Trade Size
Avg Trade Size (Sh.):	424
Avg Trade Size (Sh.) (30 D):	275
Avg Trade Size (Sh.) (90 D):	377

Institutional Trades
Total Institutional Trades:	84
Avg Institutional Trade:	$2.29M
Avg Institutional Trade (30 D):	$.59M
Avg Institutional Trade (90 D):	$.59M
Avg Institutional Trade Volume:	.22M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.82M
Avg Closing Trade (30 D):	$.76M
Avg Closing Trade (90 D):	$.76M
Avg Closing Volume:	147.97K

News

Mar 14, 2026 @ 10:01 PM VTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL,... Source: Rosen Law Firm

Mar 12, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges Vistagen T... Source: Bronstein, Gewirtz & Grossman Llc

Mar 9, 2026 @ 2:00 PM VTGN Investors Have Opportunity to Lead Vistagen T... Source: The Schall Law Firm

Mar 7, 2026 @ 2:14 PM VTGN DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM... Source: Rosen Law Firm

Mar 5, 2026 @ 5:00 PM Bronstein, Gewirtz & Grossman LLC Urges Vistagen T... Source: Bronstein, Gewirtz & Grossman Llc

Financials
	TTM	Q3 2026	Q2 2026
Basic EPS	$-1.9	$-.45	$-.54
Diluted EPS	$-1.9	$-.45	$-.54
Revenue	$.79M	$.3M	$.26M
Gross Profit
Net Income / Loss	$-67.05M	$-18.9M	$-19.42M
Operating Income / Loss	$-69.9M	$-19.55M	$-20.05M
Cost of Revenue
Net Cash Flow	$-27.34M	$-15.42M	$13.8M
PE Ratio

Splits
Jun 07, 2023	1:30
Aug 14, 2014	1:20
Jun 10, 2011	2:1